Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lantern Pharma Inc. (LTRN)

Lantern Pharma raises $4.0 million in registered direct offering at $1.09 per share

Negative Impact 3 of 5 financing Written later

Lantern Pharma sold 3,669,725 shares or pre-funded warrants at $1.09 per share in a registered direct offering that closed on September 30, 2026, for approximately $4.0 million in gross proceeds before expenses. The company also issued unregistered warrants for up to 3,669,725 shares at $1.09 that could bring in about $4 million more if fully exercised, which would add to the number of shares outstanding and dilute existing shareholders.

Key points

  • Offering priced at $1.09 per share, with approximately $4.0 million in gross proceeds before expenses; closed September 30, 2026
  • Purchase warrants for up to 3,669,725 shares at $1.09 exercise price; exercisable only after stockholder approval, expiring five years after that approval
  • Company must seek stockholder approval within 90 days of September 28, 2026
  • Placement agent Rodman & Renshaw received a cash fee of 7% of gross proceeds, and the company plans to use net proceeds for working capital and general corporate purposes

The filing

CompanyLantern Pharma Inc. (LTRN)
Form8-K, current report
Filed with the SECSep 30, 2026, 4:05 PM ET
Accession number0001493152-26-045100

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.